ResMed (RMD) – Research Analysts’ Recent Ratings Changes

ResMed (NYSE: RMD) recently received a number of ratings updates from brokerages and research firms:

• 8/11/2026 – ResMed was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/7/2026 – ResMed was given a new $213.00 price target by Robert W. Baird.
• 8/7/2026 – ResMed had its price target lowered by KeyCorp from $260.00 to $255.00. They now have an “overweight” rating on the stock.
• 8/7/2026 – ResMed had its price target raised by Royal Bank Of Canada from $234.00 to $244.00. They now have a “sector perform” rating on the stock.
• 8/7/2026 – ResMed had its price target lowered by Piper Sandler from $233.00 to $225.00. They now have a “neutral” rating on the stock.
• 8/7/2026 – ResMed had its price target lowered by Wells Fargo & Company from $225.00 to $215.00. They now have an “equal weight” rating on the stock.
• 7/24/2026 – ResMed was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 7/21/2026 – ResMed had its “buy” rating reaffirmed by UBS Group AG. They now have a $300.00 price target on the stock.
• 7/16/2026 – ResMed was downgraded by Royal Bank Of Canada from “outperform” to “sector perform”. They now have a $234.00 price target on the stock.
• 7/15/2026 – ResMed had its price target lowered by Mizuho from $235.00 to $220.00. They now have an “outperform” rating on the stock.
• 7/12/2026 – ResMed had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $235.00 price target on the stock, down from $270.00.
• 7/12/2026 – ResMed was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $235.00 price target on the stock, down from $270.00.
• 7/10/2026 – ResMed had its price target lowered by Jefferies Financial Group Inc. from $240.00 to $225.00. They now have a “hold” rating on the stock.
• 7/8/2026 – ResMed had its price target lowered by Royal Bank Of Canada from $321.00 to $276.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – ResMed had its price target lowered by Wells Fargo & Company from $227.00 to $225.00. They now have an “equal weight” rating on the stock.
• 7/1/2026 – ResMed had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 6/22/2026 – ResMed had its price target lowered by KeyCorp from $290.00 to $266.00. They now have an “overweight” rating on the stock.

ResMed Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 24th. Investors of record on Thursday, August 20th will be issued a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Thursday, August 20th. This is a positive change from ResMed’s previous quarterly dividend of $0.60. ResMed’s payout ratio is presently 23.01%.

Insider Transactions at ResMed

In other ResMed news, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $205.69, for a total transaction of $1,026,598.79. Following the sale, the chief executive officer directly owned 466,256 shares of the company’s stock, valued at $95,904,196.64. The trade was a 1.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter C. Farrell sold 8,000 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total value of $1,800,000.00. Following the completion of the transaction, the director owned 52,773 shares in the company, valued at $11,873,925. This represents a 13.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 22,973 shares of company stock worth $4,885,436 in the last three months. 0.65% of the stock is currently owned by company insiders.

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.